Clinical Trials Logo

Dopamine Dysregulation Syndrome clinical trials

View clinical trials related to Dopamine Dysregulation Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT05214404 Completed - Ulcerative Colitis Clinical Trials

Effect and Mechanism of Dopamine on Ulcerative Colitis

Start date: February 16, 2022
Phase:
Study type: Observational

Increased evidence suggests that dopamine acts as an important regulator of immune function. A substantial amount of dopamine exists in the gastrointestinal tract, especially in colonic lumen. Decreased dopamine level has been reported in the colonic mucosa of ulcerative colitis patients. Therefore, the investigators suppose that colonic dopamine could involve in the ulcerative colitis and play an important role. This study aims to explore the role of dopamine in ulcerative colitis and underlying mechanism, which will provide a rationale for diagnosis and treatment of the ulcerative colitis.

NCT ID: NCT04811807 Not yet recruiting - Parkinson Disease Clinical Trials

Clinical Response of Impulsivity After Brain Stimulation in Parkinson's Disease

CRIPS
Start date: October 2021
Phase:
Study type: Observational [Patient Registry]

The objective of this prospective observational cohort study is to answer the following clinically important questions: 1. In patients with a pre-operative history of ICBs, what is the likelihood of improvement or deterioration in ICBs post-operatively? 2. What is the risk of developing post-operative de novo ICBs after Subthalamic Nucleus DBS (STN DBS)? 3. Which factors are important in predicting changes in ICBs after STN DBS? 4. What is the impact of ICBs on carer's quality of life QoL and burden?

NCT ID: NCT03861832 Recruiting - Clinical trials for Substance Use Disorders

SMART Brain Health in African-Americans

SMART
Start date: June 16, 2018
Phase: N/A
Study type: Interventional

The investigators hypothesize that opioid use in African-Americans will be associated with hypodopaminergic alleles that alter the threshold for activating feelings of reward and pleasure within the dopaminergic system, and that these allelic frequencies will differ significantly from European Americans. Planned is a targeted system to study genetic risks for reward deficiency using risk gene panel to assign a genetic addiction risk score (GARS), comprehensive surveys to determine quality of life and exposure to stressors and trauma. This system will allow prediction of addiction and relapse potential and delivery of personalized treatment.